Intestinal flora marker for predicting curative effect of immunotherapy and application of intestinal flora marker

Abstract

The invention discloses an intestinal flora marker for predicting the curative effect of immunotherapy and application of the intestinal flora marker. The inventor screens out DNA detection targets with expression differences in patients with different clinical effects from 55 intestinal bacterium DNA detection targets, and can solve the problems that few biomarkers can be available for melanoma immunotherapy patients and the effect is not ideal. The relationship between the intestinal flora characteristics and the PD-1 / PD-L1 blocking treatment may have generality in different types of tumors; the research results of the project have the possibility of being applied to tumors except melanoma, such as sarcoma, kidney cancer, lung cancer, stomach cancer or colorectal cancer, and benefiting patients through data supplementation and reanalysis.

Description

technical field [0001] The present invention relates to the field of immunotherapy, in particular to intestinal flora markers and applications thereof for predicting the curative effect of immunotherapy. Background technique [0002] Compared with traditional treatment schemes, immunotherapy has the advantages of longer maintenance time in the body and less side effects. Although immunotherapy has achieved great success in the treatment of tumors, its effective rate is still low; the effective rate of immunotherapy for melanoma and soft tissue sarcoma is about 30%, which is not a very high rate compared with traditional treatment. efficiency. Screening patients who can benefit from immunotherapy is the key to successful treatment. Currently, the indicators that can be used to predict the efficacy of immunotherapy include tumor PD-L1 expression level and tumor mutation burden (TMB), but they are still inconclusive; immunotherapy patients face Given the lack of available bio...

AI Technical Summary

Problems solved by technology

Metagenomic sequencing can comprehensively analyze intestinal flora, but this technology has the disadvantage of being difficult to analyze bacteria into species

According to the sequencing research results of Routy et al., only Akkermansia muciniphila was found among the bacteria with significant statistical differences at the species level; most of the other bacteria with differences were at the level of phylum, family or genus; and Firmicutes, Lachnospiraceae and Erysipelotrichaceae were also effective in immunotherapy Highly expressed in the group and progression-free survival <3 months group, which makes it difficult to accurately judge or interpret the sequencing results

Images